PDS Biotechnology Reports $9.8 Million Net Loss in Q2 2026, Focuses on PDS0301 Development

PDS Biotechnology Corporation reported its financial results for the second quarter of 2026, revealing a net loss of $9.8 million, a slight increase from the $9.4 million loss recorded in the same period of 2025. For the six months ending June 30, 2026, the company reported a net loss of $17.1 million, compared to $17.9 million for the first half of 2025. The company has not generated any revenue from product sales, and its accumulated deficit has reached $233.7 million as of June 30, 2026. The company ended the quarter with $5.6 million in cash and cash equivalents, a significant decrease from $26.7 million at the end of 2025.

Operating expenses for the second quarter decreased by 15% to $6.5 million, down from $7.6 million in the prior year. This reduction was primarily driven by a 22% decrease in research and development expenses, which fell to $3.3 million from $4.2 million, attributed to lower clinical trial and manufacturing costs. General and administrative expenses also saw a decline, decreasing to $3.2 million from $3.4 million, mainly due to reduced professional fees. Despite these reductions, the company experienced an 80% increase in net interest expenses, which totaled $3.3 million for the quarter.

In terms of strategic developments, PDS Biotechnology has shifted its focus to prioritize the development of PDS0301, a tumor-targeted IL-12 immunocytokine, while discontinuing its Phase 3 trial for PDS0101 in HPV16-positive recurrent/metastatic head and neck cancer. This strategic refocus aims to enhance the company's pipeline and improve its chances of success in clinical trials. The company is also exploring partnerships to further develop PDS0101, which may provide additional funding and resources.

Operationally, PDS Biotechnology has not reported any significant changes in customer counts or user statistics, as it remains in the clinical development stage without any commercially approved products. The company continues to engage in various clinical trials for its product candidates, including PDS0301, which is being evaluated in multiple studies for different cancer indications. The company’s employee headcount remains stable, reflecting its ongoing commitment to advancing its research and development efforts.

Looking ahead, PDS Biotechnology has expressed concerns regarding its ability to continue as a going concern, citing substantial doubt about its financial viability over the next 12 months. The company plans to fund its operations through additional equity and debt financing, but it acknowledges the uncertainty surrounding its ability to secure sufficient capital. The future funding requirements will depend on various factors, including the timing and costs of clinical trials and regulatory approvals. The company remains focused on executing its development strategy while navigating the challenges of the biotechnology landscape.